As of Jul 31
| -0.08 / -4.62%|
The 4 analysts offering 12-month price forecasts for Caladrius Biosciences Inc have a median target of 12.00, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a +627.27% increase from the last price of 1.65.
The current consensus among 4 polled investment analysts is to Buy stock in Caladrius Biosciences Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.